|
|
Article: ZymoGenetics' PDGF Entering Bone Trials With BioMimetic.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
West Coast Editor
Still riding high after its $120 million initial public offering in February, ZymoGenetics Inc. is seeing more good news as its work with platelet-derived growth factor enters pivotal studies conducted by partner BioMimetic Pharmaceuticals Inc., which is targeting bone defects resulting from periodontal disease.
Nashville, Tenn.-based BioMimetic has approval from the FDA for an investigational device exemption to test PDGF (a protein that stimulates osteoblasts in the formation of new bone) with beta tricalcium phosphate (a synthetic bone substitute that provides scaffolding for bone regeneration) in a pivotal multicenter study at 11 ...
Related newspaper, magazine, and journal articles:
|
|
Article: ZYMOGENETICS, WYETH ENTER DEAL AROUND IL-13 CYTOKINE ...
BIOWORLD Today;
July 30, 2002 ;
700+ words
... ... assignment fee to ZymoGenetics for the two ... Hart told BioWorld Today. "The terms ... fever (See BioWorld Today, July 3 ... has bagged ZymoGenetics a number ... begun. (See BioWorld Today, May 30, 2002.) ZymoGenetics also has ...
|
|